Latest for Mucopolysaccharidosis Type VI
See all trialsThe week in rare diseaseEach date is the day a change was posted. Open an item to see where things stand now.
- Trial statusNo longer enrolling. Early Check: Expanded Screening in Newborns (RTI International)ClinicalTrials.gov
More about Mucopolysaccharidosis Type VI
The disease has a wide clinical spectrum. The severe, rapidly progressing form causes significant skeletal deformity, cardiac disease, and respiratory compromise that can be life-threatening by the second or third decade. Milder forms progress more slowly but still cause cumulative organ damage over time.
Keep reading about Mucopolysaccharidosis Type VI
Naglazyme (galsulfase), an enzyme replacement therapy developed by BioMarin and FDA-approved in 2005, is administered as a weekly intravenous infusion and has been shown to improve walking capacity and stair-climbing ability. Early treatment before significant organ damage has occurred leads to the best outcomes, which has driven interest in including MPS VI in newborn screening programs.
What are the symptoms of Mucopolysaccharidosis Type VI?
These are common symptoms of Mucopolysaccharidosis Type VI, and how strong they are varies from person to person.
- Short stature and progressive growth failure
- Joint stiffness and contractures limiting mobility
- Coarse facial features that become more prominent with age
- Corneal clouding and progressive vision loss
- Heart valve abnormalities including stenosis and regurgitation
- Carpal tunnel syndrome with hand numbness and weakness
- Cervical spinal stenosis with risk of spinal cord compression
- Enlarged liver and spleen (hepatosplenomegaly)
- Progressive hearing loss and recurrent ear infections
- Respiratory compromise from chest wall deformity and airway obstruction
Who gets Mucopolysaccharidosis Type VI?
Severe forms present in early childhood (ages 2-3) with rapid progression, while milder forms may not be recognized until late childhood or adolescence.
Severe cases can be life-threatening by the teens or twenties; milder forms allow survival into adulthood with reduced life expectancy. Affects males and females equally. Autosomal recessive inheritance requiring mutations in both copies of the ARSB gene. Intelligence is normal, distinguishing MPS VI from several other MPS types.
Next steps: find trials you might fitsee approved treatmentsget help payingget alerts
Which medicines are FDA-approved for Mucopolysaccharidosis Type VI?
There is currently 1 FDA-approved medication for Mucopolysaccharidosis Type VI.
Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.
How to get help paying for Mucopolysaccharidosis Type VI treatment
Charity funds and drugmaker programs for Mucopolysaccharidosis Type VI, checked at the source.
- From a charity · NORD RareCareMPS VI Medical Assistance fundOpen
Pays for: Medical and medication costs.
The foundation says: “Accepting new applications and re-enrollments for current year” - From a charity · NORD RareCareMPS VI Premium Copay Assistance fundOpen
Pays for: Insurance premiums and copays.
The foundation says: “Accepting new applications and re-enrollments for current year” - From a charity · NORD RareCareMucopolysaccharidosis type VI (MPS VI) Emergency Relief fundOpen
Pays for: Emergency relief.
The foundation says: “Accepting Applications” - From a charity · National MPS SocietyFamily Assistance Program fundApply directly
Pays for: Specialized equipment and medical aids not covered by insurance (requires insurance denial and 10% family copay), up to $3,000 per year.
The foundation says: “Status not shown on page” - From a charity · National MPS SocietyMedical Travel Assistance Program fundApply directly
Pays for: Travel to out-of-town medical appointments more than 125 miles away (per year), up to $550 per year.
The foundation says: “Status not shown on page” - From a charity · National MPS SocietyJourney Assistance Program fundApply directly
Pays for: Items that ease daily life (40% of purchase price), up to $500 per year.
The foundation says: “Status not shown on page”
Every program and fund for Mucopolysaccharidosis Type VI, by insurance →
Side effects people have reported to the FDA
Side effects people have reported to the FDA
Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.
Loading side effect data...
Diagnosis and genetic testing
Genetic testing for Mucopolysaccharidosis Type VI
Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.
Finding labs...
Trusted Mucopolysaccharidosis Type VI resources
Reputable organizations and medical references for learning more about Mucopolysaccharidosis Type VI, including disease registries, foundation resources, and clinical guidelines.